Sandoz drops JustMeds denosumab program promotion

Nicholas O’Donoghue 02/12/2025

Grassroots response pushes biosimilar manufacturer to rethink its medicine delivery service Sandoz has ceased promotion of a program aimed at boosting uptake of biosimilars after community pharmacists raised concerns about the model. Under the program GPs who prescribed Sandoz’s Jubbonti (denosumab) for a patient would be able to send the script (with patient consent) to JustMeds, rather than the patient’s usual pharmacy,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Sandoz drops JustMeds denosumab program promotion

Previous A host of awards

Next Award win for NAPSA’s Indigenous chair

MENU

ajp.com.au

Previous A host of awards

Next Award win for NAPSA’s Indigenous chair

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.